Allergan’s Commitment to Research and Development Pushes Forward

Allergan’s Commitment to Research and Development Pushes Forward

December 15, 2014
By Carolynn Grimes
The Plastic Surgery Channel

Heading into the New Year, the CEO’s of Allergan and Actavis say there will be virtually no change in Allergan’s commitment to its customers, physicians, and research and development.

 

Both companies are well run businesses that have a strong commitment to innovation and research and development.  Allergan, maker of Botox, recently agreed to be acquired for $66 billion by Actavis, who makes generic and brand-name medicines. Combining Actavis and Allergan will create one of the 10 largest global drug makers, with more than $20 billion expected in revenue next year.

Actavis CEO and President, Brent Saunders, said they would keep spending on R&D, contrasting to Valeant Pharmaceutical’s pledges to reduce research spending by 90% during their hostile takeover attempt earlier this year.  “We were very concerned about what Valeant would have done to Allergan and I think the most dramatic statement was their wanting to reduce our R & D budget by 90%. They would have come in here and basically destroyed everything except very late stage clinical development,” said David Pyott, CEO of Allergan.

Saunders said research and development is the lifeblood of Actavis, which is good news for customers and physicians who were concerned a buyout would mean an end to physician education and customer service.

Continuing a Great Track Record with the Plastic Surgery Community

wp1As the two companies entered into discussions, it became clear Actavis’ values are very similar to those of Allergan. The latter has always had close ties to the entire network of patient care, from supporting medical education to being a strong supporter of the medical societies.

“We have tremendous focus on the customer and not just the customer in the simplest of sense where we call on a doctor’s office and supply them with samples and provide them with information, but much, much broader than that,” said Pyott.

Job Cuts in the Forecast

“Our commitment to our customers and our plastic surgeons will be unwavering,” said Saunders.  “You should notice no change, and hopefully over time a stronger commitment from the combined companies. While both Pyott and Saunders are positive about the acquisition, there will be changes in staff within the two companies.  “While Brent (Saunders) and I are very open with our teams, we tell them, when mergers and acquisitions occur there has to be reductions of duplicate spending,” said Pyott.

 

Click to add a comment

More in

GalaFORM 3D mesh.

GalaFORM 3D Mesh

William P. Adams, Jr., MDApril 25, 2017
Adding implants to a breast lift: yes or no?

Adding Implants to a Breast Lift – Yes or No?

Richard J. Zienowicz, MDApril 25, 2017
Buying six-pack abs.

It’s Possible – Buying Six-Pack Abs

Dawn TongishApril 24, 2017
Skincare products from plastic surgeons.

Skincare Must-Haves According to Your Plastic Surgeon

Mark Epstein, MDApril 21, 2017
Smooth, round implants and breast aug.

Smooth, Round Implants for Natural-Looking Breasts

Katherine StuartApril 20, 2017
Four Possible Butt Implant Complications and One Great Alternative.

Four Possible Butt Implant Complications and One Great Alternative

Daniel A. Del Vecchio, MDApril 19, 2017
Rejuvenating the breasts with a breast lift.

Goodbye Push-Up Bra, Hello Breast Lift

Anne MeyerApril 18, 2017
Dermatologist or plastic surgeon for Botox injections?

Who’s the Real Botox Doc, a Dermatologist or a Plastic Surgeon?

Daniel A. Del Vecchio, MDApril 17, 2017
ALCL new FDA release.

An FYI on the FDA’s Latest Findings on ALCL and Breast Implants

John HammarleyApril 17, 2017